High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

Activating mutations in CD79 and MYD88 have recently been found in a subset of diffuse large B-cell lymphoma (DLBCL), identifying B-cell receptor and MYD88 signalling as potential therapeutic targets for personalized treatment. Here, we report the prevalence of CD79B and MYD88 mutations and their re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraan, W, Horlings, H M, van Keimpema, M, Schilder-Tol, E J M, Oud, M E C M, Scheepstra, C, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789201/
https://www.ncbi.nlm.nih.gov/pubmed/24013661
http://dx.doi.org/10.1038/bcj.2013.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789201/
https://www.ncbi.nlm.nih.gov/pubmed/24013661
http://dx.doi.org/10.1038/bcj.2013.28

Ejemplares similares